Why Is FAETH THERAPEUTICS I (FTH) Stock Up Today?

Faeth Therapeutics Inc. stock rose 5.15% to $37.98 on Tuesday, driven by a new buy rating from TD Cowen. The stock opened lower due to a 2.2% gap down from the prior close but quickly reversed course, reaching a session high of $38.41. The rally reflects growing institutional confidence in the company's pipeline and recent regulatory milestones.

What Happened

TD Cowen initiated coverage on Faeth Therapeutics with a buy rating, citing the company's progress in oncology drug development. This followed a recent announcement that the FDA granted Fast Track designation to a combination therapy involving sapanisertib and serabelisib with paclitaxel for endometrial cancer. The stock's positive momentum was further supported by recent insider buying activity, with the CFO and CEO purchasing shares in June and early July. Additional coverage from Needham and HC Wainwright & Co. reinforced the bullish sentiment, with Needham setting a $56 price target.

What The Data Shows

The stock opened at $35.31, below the prior close of $36.12, but climbed steadily throughout the session. Volume was light at 0.0M shares traded, a fraction of the 3-month average. The price closed near its session high, suggesting strong short-term demand. FTH is currently trading within its 52-week range of $7.45 to $42.14, having hit six fresh 52-week highs on September 10. The company remains unprofitable with a trailing twelve-month EPS of -82.46 and a market cap of $1.0B.

What To Watch

Investors should monitor upcoming coverage breadth and any further institutional ratings changes. The stock's performance may also be influenced by future developments in its clinical trials and regulatory interactions.